Actively Recruiting
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
Led by Mayo Clinic · Updated on 2026-03-03
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand how inflammation and insulin regulation of fat breakdown lipolysis change in people with severe obesity before and after significant, lasting weight loss through bariatric surgery. The study focuses on individuals with Class III obesity to see if inflammation in fat tissue relates to resistance to insulins effects on fat breakdown and whether weight loss after surgery reduces this inflammation. Participants will undergo gastric sleeve bariatric surgery to achieve weight loss. The study evaluates the effects of this surgery by comparing measurements taken before the procedure and about one year after. Researchers will look at inflammatory markers in fat tissue and how well insulin controls lipolysis over this period. During the study, participants will have assessments including measurements of fat tissue inflammation, gene expression related to inflammation, and insulin regulation of lipolysis before surgery and approximately one year later. The main outcomes measured are adipose macrophage content, gene expression of inflammatory markers IL-6 and TNF, and insulin regulation of lipolysis. Secondary measures include proteins involved in fat cell metabolism. The study will last over a year, including both baseline and follow-up evaluations.
CONDITIONS
Brief Title
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI between 40 and 50 kg/m2
- No active physical illness that would interfere with mobility or weight loss after bariatric surgery
- Age between 18 and 65 years
You will not qualify if you...
- Diagnosis of Type 1 or Type 2 Diabetes or fasting plasma glucose ≥126 mg/dL
- Active coronary artery disease
- Participation in structured exercise more than 2 times per week for 30 minutes or longer
- Smoking
- Use of medications affecting adipose tissue metabolism (e.g., beta blockers, corticosteroids)
- Renal insufficiency (serum creatinine > 1.5mg/dL)
- Chronic active liver disease (Bilirubin > 17mmol/L, AST > 144 IU/L, or ALT >165 IU/L)
- Pregnancy or breastfeeding
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here